HOLX
Hologic, Inc.
Hologic, Inc. insider trading
Hologic, Inc. files with the SEC as a X-Ray Apparatus & Tubes & Related Irradiation Apparatus company headquartered in Marlborough, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent HOLX insider transactions
Hologic, Inc.'s insiders made no open-market purchases or sales in the company's most recent Form 4 filings — those filings are share grants, option exercises and dispositions back to the issuer, which are compensation rather than decisions. That absence is itself worth knowing: nobody at HOLX spent or raised their own money in the market over this stretch. Two years of open-market trades are below.
SEC Form 4 data, Q3 2024 to Q2 2026
HOLX insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded HOLX on the open market: 1 purchase worth $300.8K and 13 sales worth $21M, 10 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 4 sales ($9.8M), by 2 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | −$540.9K1 sale · all on a plan | |
| Q3 2025 | — | −$9.3M3 sales · all on a plan | |
| Q2 2025 | +$300.8K1 buy | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | −$1.9M1 sale | |
| Q3 2024 | — | −$9.3M8 sales · 6 on a plan |
- Largest purchase
- +$300.8K of HOLX by Madaus Martin D (Director) on May 07, 2025.
- Largest sale
- −$5.2M of HOLX by Macmillan Stephen P (Chairman, President and CEO · Director) on Sep 22, 2025, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Stamoulis Christiana10b5-1
Director
−$540.9K
Oct 20, 2025
7,402 sh · $73.07
Macmillan Stephen P10b5-1
Chairman, President and CEO · Director
−$5.2M
Sep 22, 2025
77,418 sh · $67.04
Macmillan Stephen P10b5-1
Chairman, President and CEO · Director
−$2.6M
Sep 22, 2025
38,700 sh · $67.32
Macmillan Stephen P10b5-1
Chairman, President and CEO · Director
−$1.5M
Sep 22, 2025
22,240 sh · $66.13
Madaus Martin D
Director
+$300.8K
May 07, 2025
5,445 sh · $55.24
Mitchell Essex D
Chief Operating Officer
−$1.9M
Dec 04, 2024
24,856 sh · $76.34
Oberton Karleen Marie10b5-1
Chief Financial Officer
−$4.2M
Aug 29, 2024
52,679 sh · $80.56
Schnittker Brandon
Div. President, GYN Surgical
−$39.6K
Aug 06, 2024
476 sh · $83.11
Cohn Benjamin Jordan
Principal Accounting Officer
−$417.6K
Aug 01, 2024
5,093 sh · $81.99
Macmillan Stephen P10b5-1
Chairman, President and CEO · Director
−$1.7M
Jul 30, 2024
20,228 sh · $82.32
Macmillan Stephen P10b5-1
Chairman, President and CEO · Director
−$1.3M
Jul 30, 2024
16,177 sh · $81.44
Macmillan Stephen P10b5-1
Chairman, President and CEO · Director
−$615.3K
Jul 30, 2024
7,634 sh · $80.60
Stamoulis Christiana10b5-1
Director
−$718.6K
Jul 17, 2024
9,039 sh · $79.50
Macmillan Stephen P10b5-1
Chairman, President and CEO · Director
−$294.2K
Jul 17, 2024
3,672 sh · $80.13
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Oct 20, 2025 | Stamoulis Christiana10b5-1Director | 7,402 | $73.07 | −$540.9K |
| Sep 22, 2025 | Macmillan Stephen P10b5-1Chairman, President and CEO · Director | 77,418 | $67.04 | −$5.2M |
| Sep 22, 2025 | Macmillan Stephen P10b5-1Chairman, President and CEO · Director | 38,700 | $67.32 | −$2.6M |
| Sep 22, 2025 | Macmillan Stephen P10b5-1Chairman, President and CEO · Director | 22,240 | $66.13 | −$1.5M |
| May 07, 2025 | Madaus Martin DDirector | 5,445 | $55.24 | +$300.8K |
| Dec 04, 2024 | Mitchell Essex DChief Operating Officer | 24,856 | $76.34 | −$1.9M |
| Aug 29, 2024 | Oberton Karleen Marie10b5-1Chief Financial Officer | 52,679 | $80.56 | −$4.2M |
| Aug 06, 2024 | Schnittker BrandonDiv. President, GYN Surgical | 476 | $83.11 | −$39.6K |
| Aug 01, 2024 | Cohn Benjamin JordanPrincipal Accounting Officer | 5,093 | $81.99 | −$417.6K |
| Jul 30, 2024 | Macmillan Stephen P10b5-1Chairman, President and CEO · Director | 20,228 | $82.32 | −$1.7M |
| Jul 30, 2024 | Macmillan Stephen P10b5-1Chairman, President and CEO · Director | 16,177 | $81.44 | −$1.3M |
| Jul 30, 2024 | Macmillan Stephen P10b5-1Chairman, President and CEO · Director | 7,634 | $80.60 | −$615.3K |
| Jul 17, 2024 | Stamoulis Christiana10b5-1Director | 9,039 | $79.50 | −$718.6K |
| Jul 17, 2024 | Macmillan Stephen P10b5-1Chairman, President and CEO · Director | 3,672 | $80.13 | −$294.2K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Hologic, Inc. company record
- SEC industry classification
- X-Ray Apparatus & Tubes & Related Irradiation Apparatus
- Headquarters
- Marlborough, MA
- Incorporated in
- DE
- SEC Central Index Key
- 0000859737
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought HOLX
What the stock actually did in the 90 days following each open-market purchase
Don't check HOLX — let it ping you
Get told the moment an insider moves on HOLX
Pro watches Hologic, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add HOLX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read HOLX insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Have HOLX insiders bought or sold stock recently?
- No open-market purchases or sales by Hologic, Inc. insiders appear in the Form 4 filings scanned for this page. Grants, option exercises and tax withholding are not counted as trades.
- How much HOLX stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 7 Hologic, Inc. insiders made 1 open-market purchase worth $300.8K and 13 sales worth $21M. 10 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 4 sales ($9.8M). The largest purchase was Madaus Martin D buying $300.8K on May 07, 2025. The largest sale was Macmillan Stephen P selling $5.2M on Sep 22, 2025.
- When did an insider last buy HOLX shares?
- The most recent open-market purchase in SEC's data through Jun 30, 2026 is Madaus Martin D (Director) buying $300.8K on May 07, 2025.
- Where does HOLX insider trading data come from?
- From the Form 4 filings Hologic, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.